OCT4, a TF that can form complexes with other TFs (e.g., forkhead box protein A1 (FOXA1), androgen receptor (AR), and nuclear respiratory factor 1 (NRF1)), promotes prostate cancer (PCa) progression through epigenetic alterations and acquires chemotherapy resistance (140, 141). Here, AR is linked to prostate carcinoma.